PHVS Reiterate Market Outperform, $74 PT into Ph3 CHAPTER-3 trial of deucrictibant for HAE attack prophylaxis @ Citizens
PHVS Reiterate Market Outperform, $74 PT into Ph3 CHAPTER-3 trial of deucrictibant for HAE attack prophylaxis @ Citizens
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.